Merck, Incyte map a Phase III pipeline of their own for a frontline combo of Keytruda and epacadostat
Last fall Incyte and Merck whipped up considerable enthusiasm for a match-up of their IDO1 enzyme inhibitor and Keytruda in an early-stage study of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
